Grows human skin in the lab for patients that suffer from skin defects:
Every year, 11 mio people, half of which are children, burn large area of their skin and need hospitalization. Unfortunately, severe wounds still represent a clinical issue that
is far from being solved. Indeed, deep wounds heal badly and develop into large, permanent, disfiguring scars that need follow-up surgeries.
After years of research, CUTISS AG is now offering a solution. In their laboratories,
they develop individually customized, minimally scarring skin that surgeons all over
the world can easily transplant on their patients.
+ cover large wounds
+ minimizing scarring
+ reducing number of follow-up surgeries
+ returning lost self and social confidence
DenovoSkin has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.
The company CUTISS AG, a spin-off of the University of Zurich (UZH), was founded 2017 and is based in Zurich, Switzerland.
Thank you for reading
Business development – 営業開発・EU ・スイス ・Switzerland